表紙
市場調査レポート

ロシアのジェネリック医薬品・画期的医薬品市場の推移と予測

Generic and innovative drugs market in Russia 2014. Development forecasts for 2014-2019.

発行 PMR 商品コード 314174
出版日 ページ情報 英文 120 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
ロシアのジェネリック医薬品・画期的医薬品市場の推移と予測 Generic and innovative drugs market in Russia 2014. Development forecasts for 2014-2019.
出版日: 2014年08月01日 ページ情報: 英文 120 Pages
概要

当レポートでは、ロシアのジェネリック薬および画期的医薬品の市場について調査し、現在の市場環境、重要動向、市場規模および市場シェアの推計・予測、償還、特許、データの独占性、偽造薬などに関連する法規制の動向、主要事業者のプロファイル、売れ筋の医薬品のリストなどをまとめています。

調査内容

  • ロシアの医薬品市場全体におけるジェネリック医薬品および画期的医薬品部門のシェア
  • 市場の変化の見通し
  • 市場規模の推移と予測
  • ロシア市場で販売される偽造薬の削減に向けた政策
  • 償還プロセス・リスト・改正予定
  • データの独占性に関する法規制
  • 特許の申請手順と失効
  • ロシア市場で販売されるジェネリック医薬品および画期的医薬品の許容範囲価格
  • ロシアのPharma 2020プログラム:ジェネリック医薬品、画期的医薬品、その他の医薬品の国内製造を拡大し、外国企業を規制するためのプログラム
  • ロシアのGMP実行プロセス
  • ロシアの改訂版償還プログラム
  • ロシアのジェネリック医薬品および画期的医薬品市場における償還関連の課題
  • ロシアのジェネリック医薬品および画期的医薬品の薬価設定および値上げの手順に関する分析
  • 全体市場および個別市場の発展予測、など
目次

This unique publication uses the latest data and analyses of experienced observers to illustrate market potential and describe existing conditions, important trends and events on the market for generic and innovative drugs in Russia. It includes data on the size and market share for each segment and examines the regulatory environment in terms of reimbursement lists, patents, data exclusivity rules and counterfeit medicines.

The report also offers informative profiles of leading companies that sell generic and innovative drugs on the Russian market, lists of best-selling medications and forecasts for the development of each segment to 2019.

Get the freshest data, along with rock solid analyses of

  • The market share of the generic and innovative drugs segments as related to Russia's overall pharmaceutical market
  • Expected changes to this market as it develops from 2014-2019
  • Market value data for the period 2011-2015
  • Policies aimed at reducing the quantity of counterfeit drugs sold on the Russian market
  • Reimbursement processes, lists and proposed changes
  • Data exclusivity regulations
  • Patent processes and expirations
  • Allowable price mark ups for generic and innovative drugs sold on the Russian market.

Read about important regional programmes

  • Russia's Pharma 2020 programme, which is geared toward increasing domestic production of generic and innovative drugs and other pharmaceuticals and regulating foreign companies.
  • GMP implementation process in Russia
  • Russia's revised reimbursement programme.

This innovative report supplies

  • Complete coverage of reimbursement issues in Russia's generic and innovative drugs market
  • Analysis of pricing and mark up procedures for generic and innovative medicines in Russia
  • Reliable forecasts for market and segmental development for the period 2014-2019
  • A convenient and easily accessible source of market data, analysis and forecasts.

Questions Let this report answer them

  • How valuable is the generic and innovative drugs market in Russia
  • What do physicians think of these types of medicines Patients
  • How has the market evolved recently What will be its value in 2019
  • What type of reimbursement program operates in Russia
  • Which generic and innovative drug manufacturer is the largest in Russia
  • Which are the top selling generic and innovative medicines on the Russian market
  • Which factors determine the pricing of generic and innovative drugs in Russia
  • What are the standards for data exclusivity and patent length in Russia
  • What does the future hold in terms of changes to reimbursements and other regulatory updates

This report is a valuable asset when

  • Assembling a corporate product portfolio
  • Starting a new business on the market for generic and innovative drugs in Russia
  • Exploring Russia's regulatory structure for generic/innovative drugs
  • Keeping track of the reimbursement process
  • Assessing growth potential in this market
  • Forecasting the growth of this market to 2019.

Table of Contents

  • Methodology
  • Executive summary
    • Russia
  • Characteristics of generic and innovative drugs markets in CIS countries
    • CAGR for generic and innovative medicines for 2014-2019
    • Reimbursement and pricing policies
    • Drug patent expiry and data exclusivity periods
    • GMP standards
  • Generic and innovative drugs market in Russia
    • Key trends and events
    • Market overview
      • Share of pharmaceutical market
      • Market value and forecasts for 2011-2019
      • Attitudes towards generic and innovative drugs
    • Best-selling drugs
      • Pharmacy subgroup
      • Hospital subgroup
      • Reimbursement subgroup
    • Reimbursement and pricing policies
      • Pricing policy
      • Reimbursement system
      • Reimbursement process
      • Vital and essential drugs
      • Latest changes to ZHNVLP lists
      • Rare diseases
      • Reimbursement spending
      • Expected changes in reimbursement
    • Key players
      • Pharmacy market
      • Reimbursement subgroup
      • Hospital subgroup
      • Major events and trends associated with generic and innovative manufacturers
  • Profiles of key manufacturers
    • Profiles of selected leading innovative drugs manufacturers
    • Profiles of selected leading generic drugs manufacturers

List of Graphs

  • CAGR for innovative and generic medicines in CIS countries analysed (%), 2014-2019
  • Number of clinical trials approved in Russia, by type, 2012-Q1 2014
  • Number of clinical trials approved in Russia, by phase, 2012-Q1 2014
  • Number of patients involved in clinical trials in Russia and change (%), 2012-2013
  • Shares of generic and innovative drugs as a proportion of the pharmacy market in Russia (%), by value, 2012
  • Shares of generic and innovative drugs as a proportion of the hospital market in Russia (%), by value, 2012
  • Shares of generic and innovative drugs as a proportion of the pharmacy and hospital market in Russia (%), by value, 2012
  • Shares of generic and innovative drugs as a proportion of the pharmacy market in Russia (%), by value, July 2012-June 2013
  • Value (RUB bn) and y-o-y change (%) of the Russian generic drugs market, 2011-2019
  • Value (RUB bn) and y-o-y change (%) of the Russian innovative drugs market, 2011-2019
  • Preferences of Russians with respect to domestic and foreign medicines (%), Q4 2012
  • Awareness of differences between generic and innovative medicines in Russia (%), Q4 2012
  • Number of people who receive medicines through beneficiary drug coverage in Russia (million), 2005-2012
  • Share of domestic and imported medicines as a proportion of the DLO subgroup in Russia (%), by value, 2012
  • Share of domestic and imported medicines as a proportion of the DLO subgroup in Russia (%), by volume, 2012
  • Share of Rx and OTC medicines as a proportion of the DLO subgroup in Russia (%), by value and volume, 2012
  • Number and y-o-y change (%) of INNs on the ZHNVLP list in Russia, 2009-2013
  • Origin of medicines on the ZHNVLP lists in Russia (%), 2012-2013
  • Value (RUB bn) and volume (million packets) of the DLO subgroup in Russia, 2010-2013
  • Share of 7 categories and ONSL as a proportion of DLO spending in Russia (%), by value, 2011-2012
  • AbbVie`s operating revenue and net profit/loss in Russia (RUB m), 2012
  • AstraZeneca`s sales revenue in Russia ($ m) and y-o-y change (%), 2011-2013
  • Microgen`s sales revenue and net profit (RUB bn) in Russia, 2013
  • Nycomed/Takeda's net sales revenue and net profit/loss in Russia and CIS (€ m), 2011-2014
  • Dr. Reddy`s sales revenues (€ m) and y-o-y change (%) in Russia, FY 2005-FY 2014
  • Dr. Reddy`s sales revenues ($ m) in Russia, by segment, FY 2013-FY 2014
  • Farmak`s net sales revenue ($ m) and y-o-y change (%), 2009-2013
  • Share of individual countries as a proportion of Gedeon Richter`s female healthcare product sales value in CIS countries (%), 2013
  • Krka`s market share in selected segments in Russia (%), 2013
  • Breakdown of Pharmstandard`s sales (RUB m, %), by category, 2013
  • Ranbaxy`s sales revenues and profit after tax in Russia and Ukraine (€ m), November 2012-March 2014
  • Ranbaxy`s revenues in Russia and Ukraine (€ m) and y-o-y change (%), 2008-2013

List of Tables

  • Average weighted price per package in the DLO subgroup in Russia (RUB), 2011-2012
  • Drug price breakdown in the DLO subgroup in Russia (%), by value, 2011-2012
  • Average weighted price per packet in the hospital subgroup in Russia (RUB), domestic and imported medicines, 2012
  • Drug price breakdown in the hospital subgroup in Russia (%), domestic and imported medicines, 2012
  • Average weighted price per packet in the hospital subgroup in Russia (RUB), 2011-2012
  • Drug price breakdown in the hospital subgroup in Russia (%), by value, 2011-2012
  • Share of individual countries as a proportion of Egis` revenues in the CIS region (%), 2009/2010-2012/2013
  • Comparison of VAT rates, drug price controls, reimbursement solutions, patent protection and future developments for reimbursement system in CIS countries analysed, 2014
  • Drug patent expiry and data exclusivity periods in CIS countries analysed in comparison with EU, 2013
  • Main past trends and events and their effect on the generic and innovative drugs market in Russia, 2013-2014
  • Examples of recently established pharmaceutical clusters in Russia, 2013-2014
  • Main anticipated trends and events and their effect on the generic and innovative drugs market in Russia, 2014-2019
  • Opinions on generic and innovative medicines in Russia (%), Q4 2012
  • Top 10 best-selling innovative and generic drugs in Russia, by value, pharmacy subgroup, 2013
  • Top 10 best-selling innovative and generic drugs in Russia, by value, pharmacy subgroup, March 2014
  • Top 10 best-selling innovative and generic drugs in Russia, by value, hospital subgroup, 2013
  • Top 10 best-selling innovative and generic drugs in Russia, by value, reimbursement subgroup, 2013
  • Top 10 second level ATC categories in the DLO subgroup in Russia, by value, 2013
  • List of life-threatening and chronic progressive rare (orphan) diseases in Russia, 2014
  • DLO spending in Russia (RUB m), by category of disease, 2012
  • Expected results of the Strategy for supplying the Russian population with medications for the period until 2025, essential medicines supply, 2014-2025
  • Expected results of the Strategy for supplying the Russian population with medications for the period until 2025, mortality rates, 2014-2020
  • Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, pharmacy subgroup, 2013
  • Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, pharmacy subgroup, Q1 2014
  • Leading 5 generic and innovative pharmaceutical manufacturers in Russia, by value, 7 categories and ONSL, 2012
  • Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, reimbursement subgroup, 2013
  • Top 10 innovative pharmaceutical manufacturers in Russia, by value, hospital subgroup, 2013
  • Selected completed investments in pharmaceutical production in Russia, 2013-2014
  • Selected planned investments in pharmaceutical production in Russia, 2014-2019
  • Selected agreements pertaining to new product development and other kinds of cooperation in Russia, 2013-2014
  • Selected pharmaceutical companies acquired in Russia, 2012-2014
  • AbbVie's clinical trials carried out in CIS countries analysed, June 2014
  • Astellas' operating revenue and net profit/loss in CIS countries analysed, 2007-2012
  • Astellas' clinical trials carried out in CIS countries analysed, June 2014
  • AstraZeneca's operating revenue and net profit/loss in selected CIS countries analysed, 2010-2012
  • AstraZeneca's clinical trials carried out in CIS countries analysed, June 2014
  • Bayer's operating revenue and net profit/loss in selected CIS countries analysed, 2010-2012
  • Bayer Group AG's and Bayer HealthCare's sales revenue in Russia (€ m), 2012, 2013 and 2017
  • Bayer's clinical trials carried out in CIS countries analysed, June 2014
  • Eli Lilly's operating revenue and net profit/loss in Russia (RUB bn), 2009-2012
  • Eli Lilly's clinical trials carried out in CIS countries analysed, June 2014
  • Johnson & Johnson's operating revenue and net profit/loss in selected CIS countries analysed, 2010-2012
  • Johnson & Johnson's clinical trials carried out in CIS countries analysed, June 2014
  • Microgen's operating revenue and net profit/loss in Russia (RUB bn), 2011-2012
  • Microgen's clinical trials carried out in CIS countries analysed, June 2014
  • Novartis' operating revenue and net profit/loss in selected CIS countries analysed (€ m), 2008-2012
  • Novartis' clinical trials carried out in CIS countries analysed, June 2014
  • Nycomed/Takeda's operating revenue and net profit/loss in selected CIS countries analysed, 2007-2012
  • Takeda, selected business partners and their products in Takeda's portfolio in CIS countries, 2013
  • Nycomed/Takeda's clinical trials carried out in CIS countries analysed, June 2014
  • Roche's operating revenue and net profit/loss in selected CIS countries analysed, 2010-2012
  • Roche's clinical trials carried out in CIS countries analysed, June 2014
  • Dr. Reddy`s operating revenue and net profit/loss in Ukraine (€ m), 2011-2012
  • Egis' sales in individual CIS countries (€ m) and y-o-y change (%), 2008/2009-2012/2013
  • Farmak's operating revenue and net profit/loss in Ukraine (UAH bn), 2008-2013
  • Products launched by Farmak in Ukraine, 2013-H1 2014
  • Gedeon Richter's sales in individual CIS countries (€ m) and y-o-y change (%), 2007-Q1 2014
  • Products launched by Gedeon Richter in CIS countries, 2013-Q1 2014
  • Krka's sales in selected CIS countries (€ m) and y-o-y change (%), 2007-Q1 2014
  • Selected products launched by Krka in CIS countries analysed, 2013-Q1 2014
  • Pharmstandard's sales in individual CIS countries (€ m) and y-o-y change (%), 2009-2013
  • Pharmstandard's best-selling own generic and innovative drugs in the CIS, by value, 2013
  • Pharmstandard's best-selling own Rx generic and innovative drugs in the CIS, by value, Q1 2014
  • New products introduced on the market by Pharmstandard in the CIS countries analysed, 2013
  • New products due to be introduced on the market by Pharmstandard in the CIS countries analysed, 2014
  • Main drivers of Pharmstandard's sales growth, 2013
  • Main drivers of Pharmstandard's sales growth, Q1 2014
  • Stada's sales of generic and branded products in Russia (€ m) and y-o-y change (%), 2008-Q1 2014
  • Stada's sales of generic and branded products in Ukraine (€ m) and y-o-y change (%), 2008-Q1 2014
  • Stada's sales of generic and branded products in Kazakhstan (€ m) and y-o-y change (%), 2008-Q1 2014
  • Teva's operating revenue and net profit/loss in Ukraine (UAH m), 2010-2012
  • Teva's clinical trials carried out in CIS countries analysed, June 2014
Back to Top